Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: Gynecol Oncol. 2021 Aug 6;163(1):93–99. doi: 10.1016/j.ygyno.2021.07.033

Figure 1:

Figure 1:

CONSORT diagram. Adapted from Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/Neu (NCT01367002): updated overall survival analysis.